Each year, 12 million individuals on the planet succumb to one infection. Ninety percent
of these deaths occur in the developing world. Seventy-five per cent of them are concerned
with children. Loss of precious lives, social disturbances that also encompass severe
losses of activities (i.e. DALYs) are a major handicap to the most impoverished populations
and to the economic development of the nations in which the victims live. Embedded
in this precarious situation is the risk of emergence, reemergence and extension of
new, or renewed, infectious diseases that can spread to the other end of the planet
at the speed of modern air mass transportation. I need not cite here the most recent
pandemics that have indiscriminately affected the North and the South, but it is clear
that the greatest toll is always borne by the poorest countries.
»Each year, 12 million individuals on the planet succumb to one infection.«
This situation should not, however, cause us to lose sight of the fact that industrialized
nations also nurture their own infectious risks. Complex architectural structures
have engendered airborne infections such as legionellosis. Evolving modern medicine
places patients in a complex and potentially risky situation that combines invasive
procedures capable of delivering microbes to naturally sterile tissues and organs,
together with iatrogenic immunosuppression that severely dampens resistance mechanisms
to infectious agents. The situation is further aggravated by lingering resistance
of hospital microbes to anti-infectious agents, despite major progress made in the
control of antibiotic use over the last two decades.
In this broad context of nosocomial infections some syndromes, like sepsis and septic
shock, emerge as major threats. Both are thought to kill about 150,000 Europeans each
year. Another source of infections in our modern societies is industrialization of
the food chain. Breaches in hygiene during processing or other manipulations, or in
the cold chain that includes personal refrigerators, lead to rapid and broad dissemination
of psychrophyle microorganisms such as Listeria and Yersinia. Added to all this, ageing
of the Western population (25% of Europeans are expected to be older than 65 in 2050)
carries its own, yet complex to evaluate, risk of infectious emergence. Each year,
5,000–6,000 French citizens die of the winter epidemic of flu, a number equivalent
to traffic casualties. Vaccine protection decays with age, and a decreasing number
of lymphocytes able to ‘handle’ infecting pathogens exhaust themselves fighting chronic,
often latent viral infections like herpes viruses that have been acquired earlier
in life. The time may have come to think about delaying the age of retirement of the
immune system! Research is warranted in this crucial area. Last but not the least,
a recent explosion of studies in human genetics has shown that individuals are certainly
not equal in the face of infection. Genetic susceptibility to infectious diseases,
multigenic or Mendelian is an emerging science
»Genetic susceptibility to infectious diseases, multigenic or Mendelian is an emerging
science…«
that is expected to provide biomarkers of susceptibility or resistance to severe conditions
(i.e. meningitis, pneumonia and severe sepsis) that will take their place both in
epidemiological studies and also possibly in therapeutics, under the umbrella of what
is now called personalized medicine.
Let us try to take an optimistic view and think that molecular medicine in the field
of infectious diseases now plays a major role in their control and that it will continue
to do so in the future. One example may summarize this view and concurrently help
to better delineate what the role of EMBO Molecular Medicine could be in this complex
arena. Viral Genomic Diagnostics, following its global implementation in Western countries,
has brought the risk of accidental transmission of HIV, HBV and HCV by blood transfusion
close to zero. This is of course the result of a complex array of molecular approaches
encompassing superb basic science that led to the identification of these viruses,
development of molecular diagnostic tools such as PCR, and their global implementation.
Similar considerations apply to the recognition of HPVs as the cause of cervical cancer
and to the development of a vaccine that is now on its way to prevent the disease
both in the North and the South.
In the field of infectious diseases, a huge amount of excellent science has laid the
basis for an understanding in molecular and cellular terms of how microbes (i.e. bacteria,
viruses, parasites, yeasts and even prions) alter cellular functions. Cellular and
subcellular analyses have, with the help of the combination of imaging, molecular
biology and genomics, reached a phenomenal degree of resolution and articles describing
this research make their way into journals for various audiences, ranging from the
specialized to global. Such papers may make their way as well to EMBO Molecular Medicine
provided they are of relevance to the medical field.
However, it is a tragedy that this mass of ‘academic’ knowledge is not more efficiently
translated into innovative tools to control infectious diseases through diagnostics,
therapeutic molecules, vaccines and immunotherapeutic approaches. I often stress that
translation is an ethical obligation.
»…translation is an ethical obligation.«
The fact that it does not yet happen widely enough may simply be that the academic
sector is rarely ready, or sufficiently equipped to seize the challenge of translational
research, and to bring candidate tools to a point of visibility and credibility that
would interest the pharmaceutical/vaccine companies. A lack of communication between
the academic and industrial worlds may also be an issue. Translational research is
increasingly considered by academia, as some of its approaches, such as high-throughput
screening, provide in return molecular tools for basic research. EMBO Molecular Medicine
could become a natural medium for high profile projects that foster this virtuous
circle.
There is more than this however. Intrinsic obstacles hamper the development from the
very basic studies (i.e. cellular microbiology) of concepts that could lead to the
translational paradigm shift. A non-exhaustive list of such obstacles includes lack
of a global vision of the dynamics of infectious processes at the tissue and organ
level, human specificity of the microorganism and restriction of studies to animal
(mostly murine) models, whereas it is now clear that a switch to studies on samples
obtained from sick patients, on human primary tissue explants, or in humanized murine
models is essential, particularly in infectious immunology. Let us also consider that
certain microbes are likely to account for chronic (inflammatory) diseases that are
specifically human, as starter or sustained etiological agents. Reporting of the discovery
of such agents should without doubt make its way to EMBO Molecular Medicine. Last
but not the least, high level contributions on the genetic susceptibility and resistance
to infections, when associated to excellent epidemiological methodologies and strong
basic mechanistic studies is also an area of major interest for this Journal. This
is the field that one expects may bring the most unexpected contributions in infectious
diseases in the future and to prepare, as already mentioned, the revolution of personalized
medicine.
The agenda is broad, thus any attempt to fully define the role of EMBO Molecular Medicine
in the field of infectious diseases would be both a complex and premature endeavour.
One certitude is however that the launch of this Journal is very timely
»…the launch of this Journal is very timely…«
and that by virtue of its unique position at the interface between basic and translational
research, it offers both basic and translational researchers the opportunity to synergize
their efforts through its pages.